GEN

Health Canada Clears DxS’ K-RAS Mutation Kit as Test for Anti-EGFR Therapies

It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
The American Journal of Managed Care

FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement ...
Medical Xpress

Incurable blood cancer tied to gene mutation in new lab model

Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments and diagnostics easier and quicker, new research has found. Working with ...
ascopubs.org

ESR1 mutations kit performance with SensID ESR1 reference set 1% AF.

Toxicity differences in CDK 4/6 inhibitors seen in Asian and Pacific Islanders. Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer ...
GEN

ESR1 Mutations Kit

The APIS ESR1 Mutations Kit is an advanced qPCR assay for the detection of mutations within the estrogen receptor gene. The ESR1 Mutations Kit is described by the company as a qualitative test, ...

One overlooked detail in cancer genomes is rewriting which mutations really matter

Correlation does not equal causation. Every cancer cell has genetic mutations, but not all of those mutations necessarily ...
ascopubs.org

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape

Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...
Business Wire

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...